Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
作者信息
Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger J M, Kyburz D, Gabay C
出版信息
Ann Rheum Dis. 2006 Sep;65(9):1255-7. doi: 10.1136/ard.2005.051169. Epub 2006 Mar 15.
Abstract
摘要
相似文献
1
Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.B细胞清除疗法对肿瘤坏死因子α拮抗剂治疗无效的类风湿关节炎患者的疗效：一项开放标签观察性研究。
Ann Rheum Dis. 2006 Sep;65(9):1255-7. doi: 10.1136/ard.2005.051169. Epub 2006 Mar 15.
2
3
Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.类风湿关节炎患者接受利妥昔单抗单药治疗与接受甲氨蝶呤联合治疗的临床结局及B细胞耗竭情况比较
Ann Rheum Dis. 2008 Nov;67(11):1648-9. doi: 10.1136/ard.2007.087023.
4
Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.利妥昔单抗与抗肿瘤坏死因子-α阻滞剂联合治疗成功治愈严重难治性类风湿关节炎。
J Rheumatol. 2009 Sep;36(9):2125-6. doi: 10.3899/jrheum.090160.
5
Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.类风湿关节炎患者接受利妥昔单抗治疗后巨噬细胞功能的变化。
Ann Rheum Dis. 2007 Jun;66(6):818-20. doi: 10.1136/ard.2006.062505. Epub 2006 Dec 5.
6
Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.类风湿性关节炎：超越肿瘤坏死因子-α拮抗剂、B细胞清除和T细胞阻断。
Am J Ther. 2008 Jan-Feb;15(1):53-8. doi: 10.1097/MJT.0b013e31814daf9b.
7
B-cell therapies for rheumatoid arthritis.用于类风湿性关节炎的B细胞疗法。
Bull NYU Hosp Jt Dis. 2012;70(3):200-3.
8
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.利妥昔单抗：用于治疗类风湿关节炎的新型B细胞清除疗法。
Expert Opin Pharmacother. 2006 Dec;7(18):2559-70. doi: 10.1517/14656566.7.18.2559.
9
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.对于对抗肿瘤坏死因子药物反应不足的类风湿关节炎患者，B细胞耗竭可能比换用另一种抗肿瘤坏死因子药物更有效。
Arthritis Rheum. 2007 May;56(5):1417-23. doi: 10.1002/art.22520.
10
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.利妥昔单抗可抑制对肿瘤坏死因子抑制剂治疗反应不佳的类风湿关节炎患者的关节结构损伤。
Ann Rheum Dis. 2009 Feb;68(2):216-21. doi: 10.1136/ard.2007.085787. Epub 2008 Apr 3.
引用本文的文献
1
Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.诱导免疫耐受的纳米颗粒影响 B 和 T 淋巴细胞反应，延缓 K/BxN 小鼠的自身免疫性关节炎。
ACS Chem Biol. 2021 Oct 15;16(10):1985-1993. doi: 10.1021/acschembio.1c00212. Epub 2021 May 26.
2
Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.总结类风湿关节炎和多关节型幼年特发性关节炎中当前难治性疾病的定义：系统评价。
Rheumatology (Oxford). 2021 Aug 2;60(8):3540-3552. doi: 10.1093/rheumatology/keab237.
3
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.类风湿关节炎、强直性脊柱炎和银屑病关节炎患者接受非抗TNF靶向生物制剂时的结核病再激活风险
Mediators Inflamm. 2017;2017:8909834. doi: 10.1155/2017/8909834. Epub 2017 Jun 1.
4
Characterization of antigen-specific B cells using nominal antigen-coated flow-beads.使用名义抗原包被的流珠对抗原特异性 B 细胞进行表征。
PLoS One. 2013 Dec 30;8(12):e84273. doi: 10.1371/journal.pone.0084273. eCollection 2013.
5
Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.类风湿关节炎患者骨髓中的 Epstein-Barr 病毒可预测对利妥昔单抗治疗的反应。
Rheumatology (Oxford). 2010 Oct;49(10):1911-9. doi: 10.1093/rheumatology/keq159. Epub 2010 Jun 14.
6
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.治疗幼年特发性关节炎的生物疗法：来自成人和儿童治疗经验的启示。
Biologics. 2008 Jun;2(2):229-52. doi: 10.2147/btt.s2210.
7
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.抗CD20治疗对类风湿关节炎患者骨髓中B细胞发生的短期和长期影响。
Arthritis Res Ther. 2009;11(4):R123. doi: 10.1186/ar2789. Epub 2009 Aug 17.
8
Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study.
Open Rheumatol J. 2007;1:1-4. doi: 10.2174/1874312900701010001. Epub 2007 Sep 18.
9
B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection.对多种肿瘤坏死因子阻滞剂和白细胞介素1受体拮抗剂阿那白滞素耐药的类风湿关节炎患者的B细胞耗竭。极端阴性选择中的良好反应。
Rheumatol Int. 2007 Nov;28(1):33-7. doi: 10.1007/s00296-007-0376-8. Epub 2007 Jun 12.
10
Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.白细胞介素-10和巨噬细胞集落刺激因子在类风湿关节炎中诱导表达肿瘤坏死因子受体的巨噬细胞
Arthritis Res Ther. 2006;8(4):R126. doi: 10.1186/ar2015.
本文引用的文献
1
Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis.类风湿关节炎中滑膜炎症组织与骨髓之间的相互作用。
J Immunol. 2005 Aug 15;175(4):2579-88. doi: 10.4049/jimmunol.175.4.2579.
2
Prospects for B-cell-targeted therapy in autoimmune disease.自身免疫性疾病中B细胞靶向治疗的前景。
Rheumatology (Oxford). 2005 Feb;44(2):151-6. doi: 10.1093/rheumatology/keh446. Epub 2004 Oct 27.
3
Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.类风湿关节炎的缓解：疾病活动评分（DAS28）与美国风湿病学会初步缓解标准的一致性。
Rheumatology (Oxford). 2004 Oct;43(10):1252-5. doi: 10.1093/rheumatology/keh297. Epub 2004 Jul 6.
4
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.利妥昔单抗靶向B细胞治疗对类风湿关节炎患者的疗效。
N Engl J Med. 2004 Jun 17;350(25):2572-81. doi: 10.1056/NEJMoa032534.
5
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.类风湿关节炎的B细胞疗法：利妥昔单抗（抗CD20）的应用经验
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55.
6
Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.用于治疗风湿性疾病的肿瘤坏死因子-α拮抗剂。
Curr Opin Rheumatol. 2002 May;14(3):204-11. doi: 10.1097/00002281-200205000-00002.
7
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.包括简化关节计数在内的类风湿性关节炎改善标准的验证
Arthritis Rheum. 1998 Oct;41(10):1845-50. doi: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K.
8
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.欧洲抗风湿病联盟类风湿关节炎反应标准的制定与验证。与美国风湿病学会初步标准及世界卫生组织/国际抗风湿病联盟标准的比较。
Arthritis Rheum. 1996 Jan;39(1):34-40. doi: 10.1002/art.1780390105.
9
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.美国风湿病协会1987年修订的类风湿关节炎分类标准。
Arthritis Rheum. 1988 Mar;31(3):315-24. doi: 10.1002/art.1780310302.
Zotero 插件